HMP has assembled a leading drug research and development team (R&D) of over 300 scientists and staff based in China, which collectively form the Innovation arm of Hutchison China MediTech. The large scale, in-house and fully-integrated R&D operation work seamlessly together to discover and develop targeted therapies for oncology and immunology diseases.
Chemistry-focused R&D approach
HMP uses a chemistry-focused approach to develop highly selective small molecule tyrosine kinase inhibitors that are intended to have potentially global first-in-class efficacy or be sufficiently differentiated to be global best-in-class, next generation therapies with a superior profile compared to existing approved drugs that act against the relevant kinase targets.
This approach consists of two main pillars:
1. Developing synthetic compounds against novel targets with global first-in-class potential, which includes savolitinib (targeting c-Met), HMPL-523 (targeting Syk) and HMPL-453 (targeting FGFR1/2/3); and
2. Developing synthetic compounds against validated targets with clear differentiation to potentially be a global best-in-class/next generation therapy in their respective categories, including fruquintinib (targeting VEGFR1/2/3), sulfatinib (targeting VEGFR / FGFR1), epitinib (targeting EGFRm+ brain metastasis), theliatinib (targeting EGFR wild type) and HMPL-689 (targeting PI3K).
We have built up a broad and diversified pipeline of candidates , deliberately engineered to achieve:
• Unique selectivity to limit target-based toxicity
• High potency to optimise the dose selection with the objective to lower the required dose and thereby limit compound-based toxicity
• Chemical structures engineered to improve drug exposure in the targeted tissue
• The ability to be combined with other therapeutic agents
All differentiated drug candidates have advanced into the clinic and are currently in development in North America, Europe, Australia and Greater China.